Our platform for cell and gene therapies enables delivery of GMP lots, QC tested, and released faster and with greater predictability.
Platform Therapeutic Compatibility
Viral Vectors like AAV and Lenti
Viral and Non-Viral Cell Therapies
- Accelerates development and manufacturing timelines
- Augments unrefined processes – ideal for conserving financial and personnel resources
- Reduces outsourcing complexity – end to end solution provided by one vendor
- Alleviates industry bottlenecks such as material sourcing/supply, manufacturing/testing capacity, and talent shortages
Are platform modifications possible?
Timelines will be shorter when utilizing our defined criteria, however, our platform can accommodate certain changes with the assistance of our Process and Analytical Development teams. The best way to determine if your process falls into either a platform, hybrid, or custom would be to schedule a detailed discussion with our technical team.
Ready to discuss feasibility and timelines?
Speak to our technical team.